Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The kynurenine pathway (KP) is the major metabolic pathway of the essential amino acid tryptophan (TRP). Stimulation by inflammatory molecules, such as interferon-γ (IFN-γ), is the trigger for induction of the KP, driving a complex cascade of production of both neuroprotective and neurotoxic metabolites, and in turn, regulation of the immune response and responses of brain cells to the KP metabolites. Consequently, substantial evidence has accumulated over the past couple of decades that dysregulation of the KP and the production of neurotoxic metabolites are associated with many neuroinflammatory and neurodegenerative diseases, including Parkinson's disease, AIDS-related dementia, motor neurone disease, schizophrenia, Huntington's disease, and brain cancers. In the past decade, evidence of the link between the KP and multiple sclerosis (MS) has rapidly grown and has implicated the KP in MS pathogenesis. KP enzymes, indoleamine 2,3-dioxygenase (IDO-1) and tryptophan dioxygenase (highest expression in hepatic cells), are the principal enzymes triggering activation of the KP to produce kynurenine from TRP. This is in preference to other routes such as serotonin and melatonin production. In neurological disease, degradation of the blood-brain barrier, even if transient, allows the entry of blood monocytes into the brain parenchyma. Similar to microglia and macrophages, these cells are highly responsive to IFN-γ, which upregulates the expression of enzymes, including IDO-1, producing neurotoxic KP metabolites such as quinolinic acid. These metabolites circulate systemically or are released locally in the brain and can contribute to the excitotoxic death of oligodendrocytes and neurons in neurological disease principally by virtue of their agonist activity at N-methyl-d-aspartic acid receptors. The latest evidence is presented and discussed. The enzymes that control the checkpoints in the KP represent an attractive therapeutic target, and consequently several KP inhibitors are currently in clinical trials for other neurological diseases, and hence may make suitable candidates for MS patients. Underpinning these drug discovery endeavors, in recent years, several advances have been made in how KP metabolites are assayed in various biological fluids, and tremendous advancements have been made in how specimens are imaged to determine disease progression and involvement of various cell types and molecules in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Monitoring of Blood Vessels and Tissues by a Population of Monocytes with Patrolling Behavior
Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., Sarnacki, S., Cumano, A., Lauvau, G., & Geissmann, F. (2007) · Science · doi:10.1126/science.1142883 · Cited by 1,973
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool
Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M., & Rossi, F. M. V. (2011) · Nature Neuroscience · doi:10.1038/nn.2887 · Cited by 1,061
Three or more routes for leukocyte migration into the central nervous system
Ransohoff, R. M., Kivisäkk, P., & Kidd, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1130 · Cited by 1,052
Differential roles of microglia and monocytes in the inflamed central nervous system
Yamasaki, R., Lu, H., Butovsky, O., Ohno, N., Rietsch, A. M., Cialic, R., Wu, P. M., Doykan, C. E., Lin, J., Cotleur, A. C., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132477 · Cited by 856
A new look at cerebrospinal fluid circulation
Brinker, T., Stopa, E., Morrison, J., & Klinge, P. (2014) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-11-10 · Cited by 819 · cited 1×
“Choroid plexuses, therefore, form a functional interface between the blood and CSF circulation and the bidirectional diffusion of important molecules, models of which are constantly evolving (50).”
BackgroundQuinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Nikić, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F. M., Brück, W., Bishop, D., Misgeld, T., & Kerschensteiner, M. (2011) · Nature Medicine · doi:10.1038/nm.2324 · Cited by 713
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
Bartholomäus, I., Kawakami, N., Odoardi, F., Schläger, C., Miljkovic, D., Ellwart, J. W., Klinkert, W. E. F., Flügel-Koch, C., Issekutz, T. B., Wekerle, H., et al. (2009) · Nature · doi:10.1038/nature08478 · Cited by 685
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641 · cited 4×
“In the CNS, ~40% of KYN is locally produced, whereas 60% of KYN present is absorbed from the blood (18).”
BackgroundInfluentialQuinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Self-citationKERMODE, A. G., THOMPSON, A. J., TOFTS, P., MACMANUS, D. G., KENDALL, B. E., KINGSLEY, D. P. E., MOSELEY, I. F., RUDGE, P., & MCDONALD, W. I. (1990) · Brain · doi:10.1093/brain/113.5.1477 · Cited by 578
Guillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497
Self-citationThe new life of a centenarian: signalling functions of NAD(P)
Berger, F. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.01.007 · Cited by 489
Will the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
King, I. L., Dickendesher, T. L., & Segal, B. M. (2009) · Blood · doi:10.1182/blood-2008-07-168575 · Cited by 444
How do immune cells overcome the blood-brain barrier in multiple sclerosis?
Larochelle, C., Alvarez, J. I., & Prat, A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.066 · Cited by 405
Filippi, M., Rocca, M. A., Martino, G., Horsfield, M. A., & Comi, G. (1998) · Annals of Neurology · doi:10.1002/ana.410430616 · Cited by 395
Quinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Self-citationInterleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., Thuret, S., Price, J., & Pariante, C. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.277 · Cited by 388 · cited 1×
“Finally, in the human hippocampal progenitor cells, IL-1β treatment increased KMO and KYNU transcript levels (40).”
BackgroundKirk, J., Plumb, J., Mirakhur, M., & McQuaid, S. (2003) · The Journal of Pathology · doi:10.1002/path.1434 · Cited by 375
Siffrin, V., Radbruch, H., Glumm, R., Niesner, R., Paterka, M., Herz, J., Leuenberger, T., Lehmann, S. M., Luenstedt, S., Rinnenthal, J. L., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.018 · Cited by 325
Tavares, R. G., Tasca, C. I., Santos, C. E. S., Alves, L. B., Porciúncula, L. O., Emanuelli, T., & Souza, D. O. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00133-4 · Cited by 320
Choroid Plexus in the Central Nervous System: Biology and Physiopathology
Strazielle, N., & Ghersi-Egea, J.-F. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.7.561 · Cited by 307 · cited 1×
“Choroid plexuses (47) are specialized structures located in the borders of the ventricles, facing the lateral wall, and consist of arrangements of epithelial cells (48), which secrete CSF and contain many villi which project into the ventricular space, vascular capillaries, neuronal contacts (49), and other supporting…”
BackgroundIlluminating viral infections in the nervous system
McGavern, D. B., & Kang, S. S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2971 · Cited by 281
The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257
Self-citationKawakami, N., Nägerl, U. V., Odoardi, F., Bonhoeffer, T., Wekerle, H., & Flügel, A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050011 · Cited by 248
Lopes Pinheiro, M. A., Kooij, G., Mizee, M. R., Kamermans, A., Enzmann, G., Lyck, R., Schwaninger, M., Engelhardt, B., & de Vries, H. E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.018 · Cited by 247
Trebst, C., Lykke Sørensen, T., Kivisäkk, P., Cathcart, M. K., Hesselgesser, J., Horuk, R., Sellebjerg, F., Lassmann, H., & Ransohoff, R. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63017-9 · Cited by 242
Cramer, S. P., Simonsen, H., Frederiksen, J. L., Rostrup, E., & Larsson, H. B. W. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.12.001 · Cited by 232
Weller, R. O. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199810000-00001 · Cited by 224
Th17 Cells and Autoimmune Encephalomyelitis (EAE/MS)
Aranami, T., & Yamamura, T. (2008) · Allergology International · doi:10.2332/allergolint.r-07-159 · Cited by 218
Vos, C. M. P., Geurts, J. J. G., Montagne, L., van Haastert, E. S., Bö, L., van der Valk, P., Barkhof, F., & de Vries, H. E. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.06.012 · Cited by 188
Lestage, J., Verrier, D., Palin, K., & Dantzer, R. (2002) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00014-4 · Cited by 170 · cited 1×
“TDO is induced by corticosteroids and glucagon (26), whereas IDO-1 is induced by proinflammatory cytokines during an immune response.”
BackgroundTing, K. K., Brew, B. J., & Guillemin, G. J. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-36 · Cited by 166
Self-citationQuinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α
PEMBERTON, L. A., KERR, S. J., SMYTHE, G., & BREW, B. J. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.589 · Cited by 149
Self-citationThe kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141 · cited 1×
“In particular, the neurotoxic metabolites, the N-methyl-d-aspartic acid (NMDA) receptor agonist and excitotoxin, QUIN, the free radical generators, 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HA), and the neuroprotectants, picolinic acid (PIC), and KYNA, have significant associations with disease (19, 20)…”
BackgroundSelf-citationAnderson, J. M., Hampton, D. W., Patani, R., Pryce, G., Crowther, R. A., Reynolds, R., Franklin, R. J. M., Giovannoni, G., Compston, D. A. S., Baker, D., et al. (2008) · Brain · doi:10.1093/brain/awn119 · Cited by 141
Guillemin, G. J., Smith, D. G., Kerr, S. J., Smythe, G. A., Kapoor, V., Armati, P. J., & Brew, B. J. (2000) · Redox Report · doi:10.1179/135100000101535375 · Cited by 108
Self-citationCramer, S. P., Modvig, S., Simonsen, H. J., Frederiksen, J. L., & Larsson, H. B. W. (2015) · Brain · doi:10.1093/brain/awv203 · Cited by 94
Multiple classes of the oligodendrocyte lineage are highly vulnerable to excitotoxicity
McDonald, J. W., Levine, J. M., & Qu, Y. (1998) · NeuroReport · doi:10.1097/00001756-199808240-00014 · Cited by 92
Moreno, M. A., Burns, T., Yao, P., Miers, L., Pleasure, D., & Soulika, A. M. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.11.004 · Cited by 34
Cited by
Tryptophan metabolism and gut-brain homeostasis
Roth, W., Zadeh, K., Vekariya, R., Ge, Y., & Mohamadzadeh, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062973 · Cited by 519
Huang, Y., Zhao, M., Chen, X., Zhang, R., Le, A., Hong, M., Zhang, Y., Jia, L., Zang, W., Jiang, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0916 · Cited by 138
“Dendritic cells also express IDO1 under physiological conditions but are highly induced by traumatic, autoimmune, and neuroinflammatory diseases [15-17].”
BackgroundPeripheral and central kynurenine pathway abnormalities in major depression
Paul, E. R., Schwieler, L., Erhardt, S., Boda, S., Trepci, A., Kämpe, R., Asratian, A., Holm, L., Yngve, A., Dantzer, R., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.01.002 · Cited by 134
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · doi:10.20944/preprints202503.2399.v1 · Cited by 30
Metadata
- Authors
- Lovelace, M. D., Varney, B., Sundaram, G., Franco, N. F., Ng, M. L., Pai, S., Lim, C. K., Guillemin, G. J., & Brew, B. J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2016-08-04
- Volume
- 7
- Pages
- 246-246
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2483254822
- Cited by
- 151
- References
- 47
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.